HRP20240118T1 - Disperzivni pripravci - Google Patents
Disperzivni pripravci Download PDFInfo
- Publication number
- HRP20240118T1 HRP20240118T1 HRP20240118TT HRP20240118T HRP20240118T1 HR P20240118 T1 HRP20240118 T1 HR P20240118T1 HR P20240118T T HRP20240118T T HR P20240118TT HR P20240118 T HRP20240118 T HR P20240118T HR P20240118 T1 HRP20240118 T1 HR P20240118T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- pharmaceutically acceptable
- amino
- granules
- active ingredient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621036404 | 2016-10-24 | ||
| PCT/EP2017/077030 WO2018077815A1 (en) | 2016-10-24 | 2017-10-23 | Dispersible compositions |
| EP17794275.2A EP3528791B1 (en) | 2016-10-24 | 2017-10-23 | Dispersible compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240118T1 true HRP20240118T1 (hr) | 2024-04-12 |
Family
ID=60262899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240118TT HRP20240118T1 (hr) | 2016-10-24 | 2017-10-23 | Disperzivni pripravci |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11065198B2 (enExample) |
| EP (2) | EP3528791B1 (enExample) |
| JP (2) | JP7197474B2 (enExample) |
| KR (2) | KR20190073450A (enExample) |
| CN (1) | CN110191704A (enExample) |
| CA (1) | CA3039562A1 (enExample) |
| DK (1) | DK3528791T3 (enExample) |
| ES (1) | ES2970870T3 (enExample) |
| FI (1) | FI3528791T3 (enExample) |
| HR (1) | HRP20240118T1 (enExample) |
| HU (1) | HUE064823T2 (enExample) |
| LT (1) | LT3528791T (enExample) |
| MA (1) | MA46563B1 (enExample) |
| MX (1) | MX2019004767A (enExample) |
| PL (1) | PL3528791T3 (enExample) |
| PT (1) | PT3528791T (enExample) |
| RS (1) | RS65159B1 (enExample) |
| SI (1) | SI3528791T1 (enExample) |
| SM (1) | SMT202400060T1 (enExample) |
| TW (1) | TWI821163B (enExample) |
| WO (1) | WO2018077815A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA56449A (fr) * | 2019-07-03 | 2022-05-11 | Janssen Sciences Ireland Unlimited Co | Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine |
| WO2021104487A1 (en) | 2019-11-29 | 2021-06-03 | Aptorum Therapeutics Limited | Composition including rilpivirine and use thereof for treating tumors or cancer |
| WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
| CN114392241B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种利匹韦林片及其制备方法 |
| GB202211231D0 (en) * | 2022-08-02 | 2022-09-14 | Glaxosmithkline Ip No 2 Ltd | Novel formulation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0181966A1 (en) * | 1984-11-13 | 1986-05-28 | Gist-Brocades N.V. | Compression-coated dispersible tablets |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| US7399856B2 (en) | 2002-08-09 | 2008-07-15 | Janssen Pharmaceutica N.V. | Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile |
| SG155885A1 (en) * | 2004-09-02 | 2009-10-29 | Janssen Pharmaceutica Nv | Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile |
| CA2577288C (en) | 2004-09-02 | 2010-11-30 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| PT1632232E (pt) | 2004-09-02 | 2011-08-02 | Janssen Pharmaceutica Nv | Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo |
| PT3366278T (pt) | 2006-06-23 | 2024-10-21 | Janssen Sciences Ireland Unlimited Co | Suspensões aquosas de tmc278 |
| EP3102188A4 (en) * | 2014-02-05 | 2017-07-12 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| WO2015136294A1 (en) | 2014-03-13 | 2015-09-17 | Cipla Limited | Pharmaceutical composittion comprising rilpivirine |
| AU2015258836B2 (en) * | 2014-05-16 | 2020-07-16 | Vivus, Inc. | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use |
-
2017
- 2017-10-23 MA MA46563A patent/MA46563B1/fr unknown
- 2017-10-23 MX MX2019004767A patent/MX2019004767A/es unknown
- 2017-10-23 EP EP17794275.2A patent/EP3528791B1/en active Active
- 2017-10-23 CA CA3039562A patent/CA3039562A1/en active Pending
- 2017-10-23 RS RS20240158A patent/RS65159B1/sr unknown
- 2017-10-23 PT PT177942752T patent/PT3528791T/pt unknown
- 2017-10-23 CN CN201780065671.8A patent/CN110191704A/zh active Pending
- 2017-10-23 LT LTEPPCT/EP2017/077030T patent/LT3528791T/lt unknown
- 2017-10-23 JP JP2019521720A patent/JP7197474B2/ja active Active
- 2017-10-23 FI FIEP17794275.2T patent/FI3528791T3/fi active
- 2017-10-23 EP EP23169649.3A patent/EP4248947A3/en active Pending
- 2017-10-23 HU HUE17794275A patent/HUE064823T2/hu unknown
- 2017-10-23 WO PCT/EP2017/077030 patent/WO2018077815A1/en not_active Ceased
- 2017-10-23 SM SM20240060T patent/SMT202400060T1/it unknown
- 2017-10-23 HR HRP20240118TT patent/HRP20240118T1/hr unknown
- 2017-10-23 KR KR1020197014202A patent/KR20190073450A/ko not_active Ceased
- 2017-10-23 SI SI201731486T patent/SI3528791T1/sl unknown
- 2017-10-23 KR KR1020247001197A patent/KR102861006B1/ko active Active
- 2017-10-23 DK DK17794275.2T patent/DK3528791T3/da active
- 2017-10-23 US US16/344,143 patent/US11065198B2/en active Active
- 2017-10-23 ES ES17794275T patent/ES2970870T3/es active Active
- 2017-10-23 PL PL17794275.2T patent/PL3528791T3/pl unknown
- 2017-10-24 TW TW106136552A patent/TWI821163B/zh active
-
2021
- 2021-06-15 US US17/347,929 patent/US20220008333A1/en not_active Abandoned
-
2022
- 2022-10-14 JP JP2022165319A patent/JP2023011659A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231018T1 (hr) | Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije | |
| HRP20150798T4 (hr) | Kombinacije pirimidina koje sadrže nnrti s inhibitorima rt | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| FI3528791T3 (fi) | Dispergoituvia koostumuksia | |
| CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
| CA2484184A1 (en) | Minoxidil foam formulation | |
| NO2017063I1 (no) | Kombinasjon av: - rilpivirine hydroklorid etter en terapeutisk ekvivalent form derav, - emtricitabine og - tenofovir alafenamid eller farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamidfumarat | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| WO2011147026A3 (en) | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide | |
| BRPI0407732A (pt) | pirimidinas e triazinas inibidoras da replicação de hiv | |
| HRP20231670T1 (hr) | Farmaceutski pripravak za oralnu primjenu koji sadrži derivat aminopirimidina ili njegovu sol | |
| HRP20210223T1 (hr) | Spojevi za promicanje rasta kose i/ili sprječavanje ili odgađanje gubitka kose kod ljudi i pripravci za takve uporabe | |
| HRP20200255T1 (hr) | Formulacija ac220 osušena raspršivačem | |
| CR20210686A (es) | Análogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida | |
| FI3800177T3 (fi) | Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi | |
| BRPI0620063B8 (pt) | composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração | |
| HK1212235A1 (en) | Antiviral azasugar-containing nucleosides | |
| BR112015020443A8 (pt) | formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica | |
| JP2020500168A5 (enExample) | ||
| PE20250018A1 (es) | Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida | |
| EA201500513A1 (ru) | Продукт сомикронизации, включающий ацетат улипристала | |
| MX375427B (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion | |
| CA3010857A1 (en) | Pharmaceutical composition comprising nebivolol with improved dissolution rate | |
| WO2020086705A3 (en) | Pharmaceutical compositions and methods of making on demand solid dosage formulations | |
| HK1209027A1 (en) | Vesicular formulations, uses and methods |